NAPLEX Quiz: Indications And Scheduling

What this quiz covers

This quiz focuses on Indications And Scheduling, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Start colchicine only after allopurinol has been taken for 6 months
2. Take colchicine daily starting with allopurinol initiation to reduce flare risk (correct answer)
3. Take colchicine only as needed at the first sign of gout flare and stop allopurinol during flares
4. Take colchicine and allopurinol together only on weekends to avoid toxicity

Explanation: This question assesses the appropriate scheduling of prophylactic therapy during initiation of urate-lowering treatment for gout, emphasizing indications for flare prevention. The key patient-specific factor is the 49-year-old male's new initiation of allopurinol, which increases the risk of acute gout flares during the early treatment phase due to rapid uric acid mobilization. Taking colchicine daily starting with allopurinol initiation is the best choice as it provides effective prophylaxis against flares, aligning with guidelines recommending 3-6 months of coverage or until uric acid normalization. Starting colchicine only after 6 months of allopurinol misses the critical high-risk period for flares, while using colchicine as needed and stopping allopurinol during flares disrupts urate-lowering continuity and is not recommended. Taking both medications only on weekends lacks evidence and could lead to inconsistent efficacy and increased toxicity risks from irregular dosing. A transferable clinical pearl is that proper timing of gout prophylaxis enhances efficacy by mitigating early flares, which improves adherence, while ensuring safety through consistent low-dose regimens to avoid gastrointestinal or other adverse effects. Decision frameworks for scheduling should consider disease-specific guidelines, such as those from the American College of Rheumatology, to balance preventive benefits with long-term treatment goals.

Question 2

1. Tamsulosin 0.4 mg by mouth nightly
2. Furosemide 40 mg by mouth daily
3. Lisinopril 20 mg by mouth daily (correct answer)
4. Atorvastatin 40 mg by mouth nightly

Explanation: This question tests recognition of contraindicated drug combinations in heart failure management. The key issue is concurrent use of sacubitril/valsartan (an ARNI containing an ARB component) with lisinopril (an ACE inhibitor), which is contraindicated due to increased risk of angioedema and must be separated by a 36-hour washout period. Lisinopril should be discontinued immediately as the patient is already on sacubitril/valsartan for heart failure management. Tamsulosin appropriately treats BPH, furosemide manages volume status in heart failure, and atorvastatin is indicated for cardiovascular risk reduction. The clinical pearl is that ARNIs cannot be used with ACE inhibitors or within 36 hours of the last ACE inhibitor dose due to angioedema risk from dual neprilysin/ACE inhibition - this is a black box warning requiring careful medication reconciliation during care transitions.

Question 3

1. Naproxen can increase lithium concentrations and toxicity risk (correct answer)
2. Lithium reduces naproxen absorption and will make it ineffective
3. Topical metronidazole increases naproxen bleeding risk via CYP induction
4. Naproxen must be separated from lithium by 2 hours to avoid chelation

Explanation: This question evaluates pharmacokinetic interactions between NSAIDs and mood stabilizers. The key patient-specific factor is stable lithium levels that could be disrupted by naproxen, leading to toxicity. Choice A is most concerning as naproxen reduces lithium clearance, increasing concentrations and risk of adverse effects like tremor or confusion. Choice B is incorrect because lithium does not affect naproxen absorption; choice C is suboptimal as topical metronidazole has minimal systemic interaction; choice D is wrong since no chelation requires separation. Monitoring lithium levels during NSAID use ensures safety. A decision framework is to consider NSAID alternatives like acetaminophen in lithium patients to avoid renal effects.

Question 4

1. Albuterol HFA as needed
2. Tiotropium inhaler daily
3. Ipratropium inhaler four times daily (correct answer)
4. Tamsulosin 0.4 mg PO nightly

Explanation: This question examines anticholinergic burden and therapeutic duplication in COPD management. The key patient-specific factor is dry mouth and urinary issues from adding ipratropium to tiotropium, both anticholinergics. Choice C is the medication to discontinue as ipratropium duplicates tiotropium's action, increasing anticholinergic side effects without added benefit. Choice A is incorrect because albuterol is a complementary bronchodilator; choice B is suboptimal as tiotropium is the long-acting agent; choice D is wrong since tamsulosin is for BPH. Avoiding duplicate anticholinergics reduces adverse effects like urinary retention. A decision framework involves selecting long-acting over short-acting agents for maintenance therapy in COPD.

Question 5

1. Fluticasone propionate nasal spray 50 mcg: 2 sprays in each nostril once daily (correct answer)
2. Amoxicillin 500 mg by mouth three times daily for 7 days
3. Pantoprazole 40 mg by mouth once daily
4. Furosemide 20 mg by mouth once daily

Explanation: This question tests appropriate medication selection for seasonal allergic rhinitis. The patient presents with classic allergic rhinitis symptoms (sneezing, itchy/watery eyes) occurring most days during spring season, indicating persistent symptoms requiring controller therapy. Intranasal corticosteroids like fluticasone propionate are first-line therapy for persistent allergic rhinitis, providing superior symptom control compared to oral antihistamines. Amoxicillin (option B) is inappropriate as allergic rhinitis is not a bacterial infection, pantoprazole (option C) treats acid reflux not allergies, and furosemide (option D) is a diuretic unrelated to allergic symptoms. The clinical pearl is that intranasal corticosteroids are more effective than oral antihistamines for nasal congestion and should be used regularly throughout the allergy season for optimal benefit, with effects typically seen after 12-24 hours of consistent use.

Question 6

1. Hyperkalemia risk from spironolactone with ACE inhibitor therapy (correct answer)
2. Carvedilol should be taken only once daily to prevent bradycardia
3. Furosemide must be taken at bedtime for best diuresis
4. Metformin increases potassium and should be stopped immediately

Explanation: This question assesses electrolyte imbalances from drug combinations in heart failure management. The key patient-specific factor is hyperkalemia in a patient on lisinopril and spironolactone, both potassium-sparing agents. Choice A is most concerning as combining ACE inhibitors with aldosterone antagonists increases hyperkalemia risk, requiring monitoring or adjustment. Choice B is incorrect because carvedilol is appropriately dosed twice daily; choice C is suboptimal as furosemide morning dosing prevents nocturia; choice D is wrong since metformin does not affect potassium. Regular potassium checks are essential in such regimens for safety. A clinical pearl is to use lower doses or alternatives in renal impairment to mitigate hyperkalemia.

Question 7

1. Gabapentin dose is too high for renal function and may cause CNS adverse effects (correct answer)
2. Duloxetine should be taken only at bedtime to prevent interaction with insulin
3. Insulin lispro must be separated from gabapentin by 4 hours
4. Gabapentin is contraindicated in diabetes and should be stopped

Explanation: This question assesses dose adjustment needs for renally cleared medications in CKD patients. The key patient-specific factor is stage 4 CKD with reduced creatinine clearance, where gabapentin accumulation can cause CNS toxicity. Choice A is most concerning as gabapentin requires dose reduction in low CrCl to prevent sedation or dizziness. Choice B is incorrect because duloxetine timing does not interact with insulin; choice C is suboptimal as no separation is needed; choice D is wrong since gabapentin is indicated for neuropathy. Renal dosing guidelines ensure safety by preventing toxicity. A clinical pearl is to calculate CrCl for all renally eliminated drugs and adjust accordingly.

Question 8

1. Glipizide 10 mg PO twice daily (correct answer)
2. Metformin 1000 mg PO twice daily
3. Atorvastatin 40 mg PO nightly
4. Insulin glargine 30 units subcutaneously nightly

Explanation: This question assesses de-escalation of antidiabetic therapy in well-controlled patients experiencing hypoglycemia. The key patient-specific factor is the low A1c and hypoglycemic episodes, indicating overtreatment with insulin secretagogues. Choice A is the medication to discontinue as glipizide increases hypoglycemia risk in well-controlled diabetes and should be stopped to prevent further episodes. Choice B is incorrect because metformin is safe and foundational; choice C is suboptimal as atorvastatin is for hypertriglyceridemia; choice D is wrong since insulin glargine may still be needed but glipizide is the primary culprit. Deprescribing sulfonylureas in stable patients reduces hypoglycemia without compromising control. A clinical pearl is to monitor for symptoms and adjust therapies favoring lower hypoglycemia risk agents.

Question 9

1. TMP-SMX may increase INR and bleeding risk when taken with warfarin (correct answer)
2. Acetaminophen decreases warfarin effect, lowering INR
3. Warfarin reduces TMP-SMX effectiveness by inducing metabolism
4. TMP-SMX must be separated from warfarin by 4 hours to avoid chelation

Explanation: This question examines drug interactions affecting anticoagulation stability in patients on warfarin. The key patient-specific factor is the new TMP-SMX prescription, which can potentiate warfarin's anticoagulant effect. Choice A is most concerning as TMP-SMX inhibits warfarin metabolism, increasing INR and bleeding risk. Choice B is incorrect because acetaminophen can mildly increase INR but is less potent; choice C is suboptimal as warfarin does not induce TMP-SMX metabolism; choice D is wrong since no chelation occurs requiring separation. Monitoring INR closely during interacting antibiotic courses prevents hemorrhagic complications. A decision framework is to anticipate and adjust for antibiotics that inhibit CYP2C9 in warfarin users.

Question 10

1. Take omeprazole 20 mg at bedtime with a snack
2. Take omeprazole 20 mg 30–60 minutes before the first meal of the day (correct answer)
3. Take omeprazole 20 mg only when symptoms occur (as needed)
4. Take omeprazole 20 mg with calcium carbonate to increase absorption

Explanation: This question tests optimal scheduling of proton pump inhibitors for GERD management to maximize acid suppression. The key patient-specific factor is the need for effective heartburn control in a patient with GERD and upcoming travel, where adherence to proper timing is crucial. Choice B is the most appropriate as omeprazole should be taken 30–60 minutes before the first meal to align with peak proton pump activity for optimal efficacy. Choice A is incorrect because bedtime dosing with a snack is less effective for daytime symptoms; choice C is suboptimal as as-needed use does not provide consistent suppression; choice D is wrong since calcium carbonate may impair omeprazole absorption. Timing PPIs before meals enhances efficacy by targeting meal-stimulated acid production and improves safety by reducing long-term exposure needs. A clinical pearl is to educate patients on meal-related dosing to achieve better symptom control and adherence.

Question 11

1. Fluticasone propionate inhaler 110 mcg: 2 puffs twice daily (correct answer)
2. Ipratropium inhaler: 2 puffs four times daily
3. Azithromycin 500 mg PO daily
4. Montelukast 10 mg PO once weekly

Explanation: This question evaluates indications for controller medications in persistent asthma management. The key patient-specific factor is the patient's persistent symptoms despite rescue albuterol, indicating the need for daily anti-inflammatory therapy. Choice A is indicated as inhaled corticosteroids like fluticasone are first-line for persistent asthma to reduce inflammation and exacerbations. Choice B is incorrect as ipratropium is not a controller but a short-acting bronchodilator; choice C is suboptimal because azithromycin is for infections, not routine asthma control; choice D is wrong since montelukast is daily, not weekly, and not first-line. Using step therapy guidelines ensures appropriate escalation from rescue to controller medications. A clinical pearl is to assess symptom frequency to guide initiation of inhaled corticosteroids for long-term asthma control.

Question 12

1. Nitroglycerin 0.4 mg sublingual as needed
2. Clopidogrel 75 mg PO daily
3. Sildenafil 50 mg PO as needed for erectile dysfunction (if added later) (correct answer)
4. Atorvastatin 80 mg PO nightly

Explanation: This question addresses drug interactions involving nitrates and phosphodiesterase-5 inhibitors in post-ACS patients. The key patient-specific factor is the use of nitroglycerin, which contraindicates concurrent sildenafil due to severe hypotension risk. Choice C is correct as sildenafil requires counseling on scheduling, avoiding use within 24 hours of nitrates to prevent life-threatening interactions. Choice A is incorrect because nitroglycerin is appropriately indicated for angina relief; choice B is suboptimal as clopidogrel is standard post-ACS therapy; choice D is wrong since atorvastatin is indicated for lipid management without nitrate interaction. This interaction highlights the importance of temporal separation to ensure safety. A decision framework involves screening for erectile dysfunction treatments in nitrate users and recommending alternatives like lifestyle changes.

Question 13

1. Take nitrofurantoin 100 mg once daily at bedtime on an empty stomach
2. Take nitrofurantoin 100 mg twice daily with food (correct answer)
3. Take nitrofurantoin 100 mg twice daily with an antacid containing magnesium
4. Take nitrofurantoin 100 mg only when symptoms occur (as needed)

Explanation: This question assesses optimal scheduling of nitrofurantoin to minimize GI upset and enhance tolerability in UTI treatment. The key patient-specific factor is the need to reduce stomach upset while ensuring effective absorption for cystitis management. Choice B is most appropriate as taking nitrofurantoin with food decreases GI irritation without significantly impacting bioavailability. Choice A is incorrect because once-daily dosing is for prophylaxis, not acute treatment, and empty stomach increases nausea; choice C is suboptimal as magnesium antacids may chelate and reduce absorption; choice D is wrong since as-needed use is ineffective for infection eradication. Proper timing with meals improves adherence by enhancing safety and comfort. A clinical pearl is to counsel on food co-administration for antibiotics prone to GI side effects to optimize therapy completion.

Question 14

1. Clarithromycin can increase atorvastatin concentrations and myopathy risk (correct answer)
2. Omeprazole chelates amoxicillin and requires 4-hour separation
3. Atorvastatin reduces clarithromycin effectiveness by CYP induction
4. Amoxicillin must be taken only once daily to avoid resistance

Explanation: This question examines CYP3A4 inhibition interactions increasing statin toxicity risk. The key patient-specific factor is clarithromycin, a strong inhibitor, combined with atorvastatin, raising myopathy potential. Choice A is most concerning as clarithromycin inhibits atorvastatin metabolism, increasing concentrations and rhabdomyolysis risk. Choice B is incorrect because omeprazole does not chelate amoxicillin; choice C is suboptimal as atorvastatin does not induce clarithromycin; choice D is wrong since amoxicillin is twice daily for H. pylori. Holding or adjusting statins during macrolide therapy ensures safety. A decision framework is to check for CYP interactions in lipid-lowering regimens with new antibiotics.

Question 15

1. Take levothyroxine with ferrous sulfate each morning to improve adherence; take calcium at lunch and dinner
2. Take alendronate and calcium together on Monday morning; take levothyroxine at bedtime; take ferrous sulfate with breakfast
3. Take levothyroxine on an empty stomach in the morning; separate ferrous sulfate and calcium by at least 2 hours from levothyroxine; take alendronate alone Monday morning with water and wait at least 30 minutes before other meds/food (correct answer)
4. Take ferrous sulfate at the same time as calcium twice daily to reduce gastrointestinal upset; take levothyroxine with lunch

Explanation: This question tests medication scheduling to optimize absorption and prevent drug interactions. The key patient-specific factors are multiple medications with specific absorption requirements and potential interactions: levothyroxine requires empty stomach administration, iron and calcium can chelate other medications, and alendronate requires specific administration conditions. Option C provides the optimal schedule by separating levothyroxine from iron and calcium by at least 2 hours, ensuring alendronate is taken alone with water on an empty stomach with 30-minute wait before other medications/food. Option A incorrectly combines levothyroxine with iron (reducing thyroid hormone absorption by up to 40%), option B suggests bedtime levothyroxine which is less conventional, and option D combines iron with calcium which reduces absorption of both. The clinical pearl is that polyvalent cations (iron, calcium, magnesium, aluminum) can significantly reduce absorption of many medications through chelation, requiring temporal separation of at least 2 hours.

Question 16

1. Omeprazole 20 mg by mouth daily
2. Lisinopril 20 mg by mouth daily
3. Gabapentin 300 mg by mouth three times daily (correct answer)
4. Acetaminophen 1,000 mg by mouth three times daily as needed

Explanation: This question tests the appropriate use of gabapentin based on patient-specific indications. The key patient-specific factor is that the patient has chronic low back pain described as "aching" and worse with activity, without any neuropathic symptoms (no burning, tingling, or radiating pain). Gabapentin should be discontinued because it is only indicated for neuropathic pain conditions, not nociceptive/mechanical pain like this patient's osteoarthritis-related back pain. Omeprazole is appropriately treating GERD, lisinopril is managing hypertension, and acetaminophen is a first-line option for osteoarthritis pain. The clinical pearl is that gabapentin lacks efficacy for non-neuropathic pain and should be reserved for conditions with clear neuropathic features to avoid unnecessary medication exposure and potential side effects like sedation and dizziness.

Question 17

1. TMP-SMX with glipizide (increased risk of hypoglycemia) (correct answer)
2. TMP-SMX with metformin (complete loss of glycemic efficacy)
3. TMP-SMX with lisinopril (increased risk of cough only)
4. Glipizide with metformin (contraindicated combination in type 2 diabetes)

Explanation: This question tests recognition of drug interactions causing hypoglycemia in diabetic patients. The key interaction is between trimethoprim-sulfamethoxazole (TMP-SMX) and glipizide, where TMP-SMX inhibits CYP2C9, reducing glipizide metabolism and increasing its blood levels, leading to enhanced hypoglycemic effects manifesting as shakiness and sweating. This interaction is most concerning because hypoglycemia can be dangerous, especially in a patient with CKD who may have reduced drug clearance. Option B is incorrect as TMP-SMX doesn't eliminate metformin's efficacy, option C wrongly suggests the only effect with lisinopril is increased cough (the real concern would be hyperkalemia), and option D is false as glipizide and metformin are commonly used together in diabetes. The clinical pearl is that sulfonamide antibiotics can potentiate sulfonylurea hypoglycemia through both CYP inhibition and protein binding displacement - patients should monitor blood glucose more frequently and may need sulfonylurea dose reduction during antibiotic therapy.

Question 18

1. Sertraline: take only at bedtime and skip doses on weekends to reduce side effects
2. Ethinyl estradiol/levonorgestrel: take 1 tablet at the same time daily; if starting today (quick start), use backup contraception for 7 days (correct answer)
3. Ethinyl estradiol/levonorgestrel: take 2 tablets daily for the first week to reach steady state faster
4. Ethinyl estradiol/levonorgestrel: take only on days of intercourse and stop when not needed

Explanation: This question tests proper initiation and scheduling of combined oral contraceptives for optimal efficacy. The key counseling point is that combined oral contraceptives must be taken at the same time daily to maintain stable hormone levels and contraceptive efficacy, with backup contraception needed for 7 days if using the "quick start" method (starting immediately rather than waiting for menses). Option B correctly identifies this need for consistent daily timing and backup protection. Option A incorrectly suggests weekend dose-skipping for sertraline which would destabilize antidepressant therapy, option C wrongly recommends doubling the contraceptive dose, and option D dangerously suggests intermittent use which provides no contraceptive protection. The clinical pearl is that consistent daily administration of oral contraceptives at the same time (within a 3-hour window) optimizes efficacy - missed doses or erratic timing increases breakthrough bleeding and pregnancy risk, requiring specific missed-dose protocols based on timing.

Question 19

1. Continue taking doxycycline with the prenatal vitamin and magnesium to reduce stomach upset
2. Separate doxycycline from iron- and magnesium-containing products by at least 2 hours before or 4–6 hours after; take doxycycline with a full glass of water and avoid lying down immediately (correct answer)
3. Take doxycycline only at bedtime with the prenatal vitamin to maximize absorption
4. Stop the prenatal vitamin while taking doxycycline because they cannot be used together

Explanation: This question tests management of tetracycline-polyvalent cation interactions affecting drug absorption. The key issue is that doxycycline forms insoluble chelate complexes with iron (in prenatal vitamin) and magnesium, reducing its bioavailability by up to 80% when taken together. The optimal strategy is temporal separation: take doxycycline at least 2 hours before or 4-6 hours after iron/magnesium-containing products, with a full glass of water, avoiding immediate recumbency to prevent esophageal irritation. Option A incorrectly suggests taking them together, option C's bedtime administration with prenatal vitamin maintains the interaction, and option D unnecessarily stops the prenatal vitamin when separation is sufficient. The clinical pearl is that tetracycline antibiotics require careful scheduling around dairy products, antacids, and supplements containing calcium, iron, magnesium, or aluminum - proper separation preserves antibiotic efficacy while allowing continued use of necessary supplements.

Question 20

1. Clopidogrel 75 mg daily with omeprazole 20 mg daily (reduced antiplatelet activation) (correct answer)
2. Atorvastatin 80 mg nightly with metformin 1,000 mg twice daily (increased risk of hypoglycemia)
3. Amlodipine 10 mg daily with omeprazole 20 mg daily (loss of blood pressure control)
4. Clopidogrel 75 mg daily with atorvastatin 80 mg nightly (complete loss of statin efficacy)

Explanation: This question tests recognition of clinically significant drug-drug interactions in a post-TIA patient. The key interaction is between clopidogrel and omeprazole, where omeprazole (a CYP2C19 inhibitor) reduces the conversion of clopidogrel to its active metabolite, potentially decreasing antiplatelet efficacy by 25-50%. This interaction is most concerning because reduced antiplatelet activity increases the risk of recurrent cerebrovascular events in this high-risk post-TIA patient. Option B is incorrect as there's no interaction between atorvastatin and metformin causing hypoglycemia, option C is false as omeprazole doesn't affect amlodipine's blood pressure control, and option D is wrong as clopidogrel doesn't affect statin efficacy. The clinical pearl is that PPIs vary in their CYP2C19 inhibition potential - pantoprazole or lansoprazole are preferred over omeprazole/esomeprazole when concurrent clopidogrel is necessary. The FDA specifically warns against this combination due to reduced cardiovascular protection.